Platform Technology To Speed Up CMC Process

Logo
Presented by

Dr H. Fai Poon, President, QuaCell Biotech Ltd

About this talk

The commercial success of monoclonal antibodies has made biologics become attractive to pharmaceutical companies . The approval pathway is often required to extensive chemistry, manufacturing and control (CMC) study to ensure the long‐term safety and efficacy of biologics. However, the CMC studies remains labor intensive and time consuming. Reduction of CMC time has become one of the most important technological advantages for a biological therapeutic developer. Therefore, the ability to develop a biologically active molecule at the short duration via cell culture platform has become the key of successful biologic development. The priority of biologic companies is to acquire and develop cell culture technology platforms that enable them to speed up their CMC process; and to reach clinical trials quickly. Hence, we will discuss current cell culture technologies that are relevant to CMC development.
Related topics:

More from this channel

Upcoming talks (39)
On-demand talks (353)
Subscribers (36566)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.